SELP and sickle cell disease: As platelet P selectin is a critical regulator of platelet-neutrophil interactions and anti–P selectin therapy was recently FDA approved for the treatment of sickle-cell disease, we assessed tested P selectin blockade in hPAR4Thr/Thr mice subjected to stroke.